Narix Pharmaceuticals Private Limited

Pretomanid Tablet Nitroimidazole Core of BPaL Regimen for XDR-TB Narix Pharmaceuticals Narix Pharmaceuticals supplies Pretomanid Tablets, a bicyclic nitroimidazole with dual mechanism � inhibits mycolic acid synthesis aerobically and generates reactive nitrogen species anaerobically � making it active against both replicating and non-replicating M. tuberculosis. Core of the WHO-recommended BPaL (Bedaquiline + Pretomanid + Linezolid) regimen. Key Therapeutic Uses: � XDR-TB and treatment-intolerant MDR-TB � BPaL regimen � 6-month BPaL regimen � 90% cure rate in trials � Highly drug-resistant TB cases � TB with multiple prior treatment failures Available Strengths: 200 mg Product Highlights: � Core BPaL regimen component � 90% cure in XDR-TB � Dual mechanism � aerobic + anaerobic TB activity � WHO-GMP, DCGI approved � PCD pharma franchise & bulk export Certifications: WHO-GMP ISO 9001:2015 DCGI Schedule M #PretomanidTablet #BPaLRegimen #XDRTBMedicine #MDRTBTablet #NitroimidazoleTB #PretomanidManufacturer #PCDPharma #WHOGMPCertified #NarixPharmaceuticals #GenericMedicine